Skip to content

Diagnostic biomarkers of lung cancer and pulmonary nodules based on exhaled breath, urine and saliva

Diagnostic biomarkers of lung cancer and pulmonary nodules based on exhaled breath, urine and saliva

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045043
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-05
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer, Pulmonary nodules

Interventions

urine.
Gold Standard:CT examination showed solitary or multiple pulmonary nodules
Index test:1.Volatile&#32
in&#32
2.Specific&#32
and&#32

Sponsors

Xijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.CT examination showed that there were solitary or multiple nodules in the lung; 2.18-80 years old; 3.The patient was clinically fit and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with severe underlying diseases were not suitable for the study; 2.Acute respiratory tract infections (fungi, bacteria, viruses, tuberculosis, etc.) were confirmed within one month; 3.Malignant tumors of other systems have been diagnosed; 4.Patients with diabetes, bronchial asthma, severe liver damage, end-stage renal disease and acute inflammation; 5.Patients were treated with radiotherapy, chemotherapy, targeted therapy and other anti-tumor therapy before enrollment; 6.Calcified nodule.

Design outcomes

Primary

MeasureTime frame
Volatile organic compounds;Urine specific metabolites;Salivary specific metabolites;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public Contactlv Xing

Xijing Hospital

lvxing89719@126.com+86 13709258441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026